Renal biomarkers for the prediction of cardiovascular disease

Current Opinion in Cardiology

Volumn 30, Issue 4, 2015, Pages 454-460

  Joshi, Supriya ^a   Viljoen, Adie ^a  

^a LISTER HOSPITAL   (United Kingdom)

Author keywords

Albuminuria; Biomarkers; Fibroblast growth factor 23; Neutrophil gelatinase associated lipocalin; Parathyroid hormone

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; FIBROBLAST GROWTH FACTOR 23; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOCALIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PARATHYROID HORMONE; URIC ACID;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; CREATININE URINE LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; NEUTROPHIL; NEUTROPHIL GRANULE; PREDICTION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM; PROGNOSIS; RISK FACTOR;

BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84942576044     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000177     Document Type: Review

References (79)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
2. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-2169.
3. Price CP. Evidence-based laboratory medicine: supporting decision-making. Clin Chem 2000; 46 (8 Pt 1):1041-1050.
4. Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009; 55:1932-1943.
5. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80:17-28.
6. Grubb A, Horio M, Hansson LO, et al. Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator. Clin Chem 2014; 60:974-986.
7. Kilbride HS, Stevens PE, Eaglestone G, et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. Am J Kidney Dis 2013; 61:57-66.
8. Beilby J, Divitini ML, Knuiman MW, et al. Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population. Clin Chem 2010; 56:799-804.
9. Ito H, Pacold IV, Durazo-Arvizu R, et al. The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multiethnic study of atherosclerosis. Am J Epidemiol 2011; 174:949-957.
10. Rule AD, Lieske JC. Cystatin C is more than GFR, and this may be a good thing. J Am Soc Nephrol 2011; 22:795-797.
11. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
12. Shlipak MG, Matsushita K, Ä rnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369: 932-943.
13. Ferraro S, Marano G, Biganzoli EM, et al. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin Chem Lab Med 2011; 49:1397-1404.
14. Qing X, Furong W, Yunxia L, et al. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol 2012; 11:108.
15. Patel D, Ahmad S, Silverman A, Lindsay J. Effect of cystatin C levels on angiographic atherosclerosis progression and events among postmenopausal women with angiographically decompensated coronary artery disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study). Am J Cardiol 2013; 111:1681-1687.
16. Svensson-Farbom P, Ohlson Andersson M, Almgren P, et al. Cystatin C identifies cardiovascular risk better than creatinine-based estimates of glomerular filtration in middle-aged individuals without a history of cardiovascular disease. J Intern Med 2014; 275:506-521.
17. Lee M, Saver JL, Huang WH, et al. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes 2010; 3:675-683.
18. Seronie-Vivien S, Delanaye P, Pieroni L, et al. Cystatin C: current position and future prospects. Clin Chem Lab Med 2008; 46:1664-1686.
19. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
20. Wu HY, Peng YS, Chiang CK, et al. Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuria screening in patients with diabetes mellitus: a systematic review and meta-analysis. JAMA Intern Med 2014; 174:1108-1115.
21. Younes N, Cleary PA, Steffes MW, et al. Comparison of urinary albumincreatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Clin J Am Soc Nephrol 2010; 5:1235-1242.
22. Naresh CN, Hayen A, Weening A, et al. Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis 2013; 62:1095-1101.
23. Carter CE, Gansevoort RT, Scheven L, et al. Influence of urine creatinine on the relationship between the albumin-to-creatinine ratio and cardiovascular events. Clin J Am Soc Nephrol 2012; 7:595-603.
24. Miller WG, Bruns DE, Hortin GL, et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009; 55:24-38.
25. Seegmiller JC, Sviridov D, Larson TS, et al. Comparison of urinary albumin quantification by immunoturbidimetry, competitive immunoassay, and proteincleavage liquid chromatography-tandem mass spectrometry. Clin Chem 2009; 55:1991-1994.
26. Itoh Y, Ichihara K, Kishi K, et al. Preparation of highly purified monomeric human serum albumin as secondary reference material for standardization of urinary albumin immunoassays. Clin Chim Acta 2012; 413:175-181.
27. Solomon SD, Lin J, Solomon CG, et al. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 2007; 116:2687-2693.
28. Asselbergs FW, Diercks GFH, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809-2816.
29. Cai L, Rubin J, Han W, et al. The origin of multiple molecular forms in urine of HNL/NGAL. Clin J Am Soc Nephrol 2010; 5:2229-2235.
30. Makris K, Markou N, Evodia E, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 2009; 47:79-82.
31. Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem 2014; 51:335-351.
32. Lippi G, Aloe R, Storelli A, et al. Evaluation of NGAL Test, a fully-automated neutrophil gelatinase-associated lipocalin (NGAL) immunoassay on Beckman Coulter AU 5822. Clin Chem Lab Med 2012; 50:1581-1584.
33. Lippi G, Plebani M. Neutrophil gelatinase-associated lipocalin (NGAL): the laboratory perspective. Clin Chem Lab Med 2012; 50:1483-1487.
34. van Deursen VM, Damman K, Voors AA, et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail 2014; 7:35-42.
35. Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011; 13:846-851.
36. Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail 2005; 7:1059-1069.
37. Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol 2011; 22:1748-1757.
38. Daniels LB, Barrett-Connor E, Clopton P, et al. Plasma neutrophil gelatinaseassociated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study. J Am Coll Cardiol 2012; 59:1101-1109.
39. Haapio M, House AA, de Cal M, et al. Heart-kidney biomarkers in patients undergoing cardiac stress testing. Int J Nephrol 2011; 2011:425923.
40. Choi KM, Lee JS, Kim EJ, et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008; 158:203-207.
41. Zografos T, Haliassos A, Korovesis S, et al. Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am J Cardiol 2009; 104:917-920.
42. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314:409-414.
43. Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78:975-980.
44. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64:2272-2279.
45. van Husen M, Fischer AK, Lehnhardt A, et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010; 78:200-206.
46. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79:1370-1378.
47. Taal MW, Thurston V, McIntyre NJ, et al. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Kidney Int 2014; 86:407-413.
48. Ix JH, Katz R, Kestenbaum BR, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60:200-207.
49. Vervloet MG, van Zuilen AD, Heijboer AC, et al. Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. BMC Nephrol 2012; 13:20.
50. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205:385-390.
51. Yilmaz MI, Sonmez A, Saglam M, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78:679-685.
52. Smith ER, Cai MM, McMahon LP, Holt SG. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 2012; 97:3357-3365.
53. Smith ER, McMahon LP, Holt SG. Fibroblast growth factor 23. Ann Clin Biochem 2014; 51 (Pt 2):203-227.
54. Kendrick J, Cheung AK, Kaufman JS, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22:1913-1922.
55. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432-2439.
56. Lutsey PL, Alonso A, Selvin E, et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc 2014; 3:e000936.
57. Kestenbaum B, Sachs MC, Hoofnagle AN, et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail 2014; 7:409-417.
58. Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals followup study. Clin J Am Soc Nephrol 2011; 6:2871-2878.
59. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152:640-648.
60. Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJA. PTH-a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol 2013; 8:299-312.
61. Hedback G, Tisell LE, Bengtsson BA, et al. Premature death in patients operated on for primary hyperparathyroidism. World J Surg 1990; 14:829-835; discussion 836.
62. Folsom AR, Alonso A, Misialek JR, et al. Parathyroid hormone concentration and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2014; 168:296-302.
63. Jassal SK, Chonchol M, von Muhlen D, et al. Vitamin d, parathyroid hormone, and cardiovascular mortality in older adults: the Rancho Bernardo study. Am J Med 2010; 123:1114-1120.
64. Kestenbaum B, Katz R, de Boer I, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol 2011; 58:1433-1441.
65. Welsh P, Doolin O, McConnachie A, et al. Circulating 25OHD, dietary vitamin D, PTH, and calcium associations with incident cardiovascular disease and mortality: the MIDSPAN Family Study. J Clin Endocrinol Metab 2012; 97:4578-4587.
66. van Ballegooijen AJ, Reinders I, Visser M, et al. Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab 2013; 98:E638-E645.
67. van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA. Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J 2013; 165:655-664; 664. e1-5.
68. Wannamethee SG, Welsh P, Papacosta O, et al. Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease. Circ Heart Fail 2014; 7:732-739.
69. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010; 31:1591-1598.
70. Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calciumand risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and metaanalysis. JAMA 2011; 305:1119-1127.
71. Natoli JL, Boer R, Nathanson BH, et al. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A metaanalysis. BMC Nephrol 2013; 14:88.
72. Ballinger AE, Palmer SC, Nistor I, et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2014; 12:Cd006254.
73. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22:118-127.
74. Liu WC, Hung CC, Chen SC, et al. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2012; 7:541-548.
75. Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009; 53:796-803.
76. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5:1388-1393.
77. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011; 6:1887-1894.
78. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; 5:Cd007784.
79. Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54:810-819.